Nivolumab before and after allogeneic hematopoietic cell transplantation

Bone Marrow Transplant. 2017 Jul;52(7):1054-1056. doi: 10.1038/bmt.2017.44. Epub 2017 Mar 27.

Authors

F Covut¹, R Pinto¹, B W Cooper^{1

2}, B Tomlinson^{1

2}, L Metheny^{1

2}, E Malek^{1

2}, H M Lazarus^{1

2}, M de Lima^{1

2}, P F Caimi^{1

2}

Affiliations

¹ Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.
² Case Comprehensive Cancer Center, Cleveland, OH, USA.

PMID: 28346414
DOI: 10.1038/bmt.2017.44

No abstract available

Publication types

Case Reports

MeSH terms

Adolescent
Adult
Allografts
Antibodies, Monoclonal / administration & dosage*
Female
Hematopoietic Stem Cell Transplantation*
Hodgkin Disease / pathology
Hodgkin Disease / therapy*
Humans
Male
Middle Aged
Nivolumab

Substances

Antibodies, Monoclonal
Nivolumab